Comparison of autologous platelet-rich plasma and corticosteroid injection in the treatment of chronic plantar fasciitis
1 Senior Resident, Department of Orthopaedics, School of Medical Sciences and Research Sharda University, Greater Noida, Uttar Pradesh, India.
2 Professor, Department of Orthopaedics, School of Medical Sciences and Research Sharda University, Greater Noida, Uttar Pradesh, India.
3 Associate Professor, Department of Orthopaedics, School of Medical Sciences and Research Sharda University, Greater Noida, Uttar Pradesh, India.
4 Resident, Department of Orthopaedics, School of Medical Sciences and Research Sharda University, Greater Noida, Uttar Pradesh, India.
Research Article
International Journal of Frontiers in Medicine and Surgery Research, 2023, 03(02), 042–050.
Article DOI: 10.53294/ijfmsr.2023.3.2.0071
Publication history:
Received on 17 June 2023; revised on 04 August 2023; accepted on 07 August 2023
Abstract:
Chronic plantar fasciitis is one of the leading causes of heel pain and medical professionals can find it difficult to treat successfully over the long term. Due to any factor which increases tension on the medial calcaneal tuberosity insert (e.g., running, walking, prolonged standing, pes cavus, pes planus, overpronation), results in local inflammation. While the results of the use of platelet-rich plasma to treat chronic plantar fasciitis were encouraging, there is little documentation that compares the long-term effectiveness of chronic plantar fasciitis with steroid injection. It stimulates wound healing, bone healing, and tendon healing by releasing platelet-derived growth factors. This prospective randomized study is conducted to compare the efficacy of platelet-rich plasma and local injection of corticosteroid.
Keywords:
plantar fascia, fasciitis, heel pain, intra-articular injection
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0